Gilead Sciences (GILD) Stock Rallying Today After Earnings Beat

NEW YORK (TheStreet) -- Shares of Gilead Sciences Inc  (GILD) are rallying up 5.28% to $105.82 in afternoon trading Friday, following the company's better than expected first quarter earnings results.

For the first quarter, Gilead earned $2.94 per share versus the consensus estimate of $2.32 per share.

Revenue came in at $7.59 billion for the period, also surpassing the consensus estimate of $6.92 billion.

The company also issued a higher guidance for the full year, compared to its previous forecast.

For 2015, the company now expects net product sales of between $28 billion to $29 billion, versus its prior forecast of $26 billion to $27 billion.

Gilead is a research-based biopharmaceutical company that discovers, develops and commercializes medicines.

The company's primary areas of focus include human immunodeficiency virus, liver diseases, oncology and respiratory conditions.

Gilead's products include Atripla, Truvada, Viread, Complera/Eviplera, Emtriva, Hepsera, Letairis, Ranexa, Lexiscan/Rapiscan, AmBisome, Vistide, Macugen, Cayston and Tamiflu.

Separately, TheStreet Ratings team rates GILEAD SCIENCES INC as a Buy with a ratings score of A. TheStreet Ratings Team has this to say about their recommendation:

"We rate GILEAD SCIENCES INC (GILD) a BUY. This is based on the convergence of positive investment measures, which should help this stock outperform the majority of stocks that we rate. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, impressive record of earnings per share growth, compelling growth in net income and notable return on equity. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook."

You can view the full analysis from the report here: GILD Ratings Report

GILD ChartGILD data by YCharts

If you liked this article you might like

Stock Market Drop Not Seen Dampening Healthcare Deal Activity

Stock Market Drop Not Seen Dampening Healthcare Deal Activity

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Centene, LabCorp Among Healthcare Stock Gainers

Centene, LabCorp Among Healthcare Stock Gainers

A Regular Winning Trade Becomes Roadkill in Market Meltdown

A Regular Winning Trade Becomes Roadkill in Market Meltdown

These 2 Biotech Stocks Still Have Upside

These 2 Biotech Stocks Still Have Upside